2025-10-17 - Analysis Report
Okay, let's analyze UnitedHealth Group (UNH) based on the data you've provided.

## UnitedHealth Group (UNH) Stock Analysis

**Company Overview:** UnitedHealth Group Inc. is a diversified health care company providing a wide range of products and services.

### 1. Relative Performance & Alpha/Beta Analysis

*   **UNH Cumulative Return:** -15.97%
*   **S&P 500 (VOO) Cumulative Return:** 96.43%
*   **Absolute Divergence:** -115.9
*   **Relative Divergence:** 8.9

**Analysis:** UNH has significantly underperformed the S&P 500. The relative divergence of 8.9 suggests it is near the lowest end of its historical divergence range relative to the S&P 500, indicating substantial underperformance compared to its historical performance relative to the index.

**Alpha/Beta & Performance Table Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2015-2017  | 58.0% | 66.4% | 30.0% | 0.1  | 197.9  |
| 2016-2018  | 41.0% | 70.4% | 26.0% | 0.1  | 223.6  |
| 2017-2019  | 36.0% | 73.8% | 14.0% | 0.2  | 263.8  |
| 2018-2020  | -43.0%| 81.2% | -67.0%| 0.5  | 314.7  |
| 2019-2021  | 16.0% | 81.2% | -30.0%| 1.5  | 450.7  |
| 2020-2022  | -1.0%| 81.2% | 0.0% | 1.5  | 475.8  |
| 2021-2023  | 24.0% | 80.8% | 23.0% | 0.4  | 472.5  |
| 2022-2024  | -27.0%| 78.8% | -47.0%| 0.3  | 454.0  |
| 2023-2025  | -58.0%| 78.8% | -119.0%| 1.3  | 323.0  |

*   **CAGR:** The Compound Annual Growth Rate has varied significantly over different periods, with strong positive growth in earlier periods (2015-2019) and negative growth in recent periods (2018-2025). The CAGR has declined sharply, indicating poor recent performance.
*   **MDD:** The Maximum Drawdown is consistently high, ranging from 66.4% to 81.2%, reflecting significant volatility and risk associated with UNH stock.
*   **Alpha:** Alpha has turned negative in recent periods (2018-2025), indicating underperformance relative to its benchmark. The negative alpha suggests UNH is not generating excess returns based on its risk profile.
*   **Beta:** Beta varies but shows an increase in certain periods (e.g., 2019-2022), indicating higher sensitivity to market movements during those times.
*   **Cap(B):** Market capitalization has generally increased over time, peaking in 2020-2022 before decreasing in recent years, aligning with the stock's poor performance.

### 2. Recent Price Action

*   **Current Price:** 359.93
*   **Last Market Price:** 356.67
*   **Previous Close:** 361.15
*   **Change:** -1.24
*   **5-day Moving Average:** 359.86
*   **20-day Moving Average:** 351.04
*   **60-day Moving Average:** 312.36

**Analysis:** The stock is currently trading slightly below its 5-day moving average and above its 20 and 60-day moving averages. The negative change in the last market price indicates a recent downward trend. The price dropping below the previous close suggests a negative sentiment in the very short term.

### 3. Technical Indicators & Market Risk

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 56.89 (Neutral)
*   **PPO:** -0.3988 (Slightly Bearish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (2 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Divergence Change:** 0.0 (Short-term decrease)
*   **Expected Return:** -145.3% (Significant underperformance vs. S&P 500 over 2+ year horizon)

**Analysis:**

*   The MRI of 0.8 suggests a medium level of investment risk.
*   The RSI is neutral, indicating neither overbought nor oversold conditions.
*   The negative PPO suggests a slightly bearish trend.
*   The Hybrid Signal suggests a bullish outlook with a high MRI of 0.90, recommending a full investment of cash. This signal should be viewed cautiously given the other indicators.
*   The 20-day relative divergence indicates a short-term decrease.
*   The expected return is significantly negative, suggesting substantial underperformance compared to the S&P 500.
*   The negative change in last market price (price': 356.67, 'previousClose': 361.15, 'change': -1.24) does indicate a negative short-term movement, though not necessarily a "sharp" drop.

### 4. Recent News & Events

*   **Medicare Advantage:** Articles discussing Medicare Advantage plans may influence investor sentiment due to potential policy changes and regulatory impacts.
*   **Optum Growth:** Positive news about Optum's growth is generally good for UnitedHealth stock, as Optum is a significant part of UNH's business.
*   **CVS Health:** Articles about competitors like CVS Health may provide insights into the broader healthcare industry and competitive landscape.
*   **Debt Management:** Articles highlighting UnitedHealth's ability to manage debt can reassure investors about the company's financial stability.
*   **Investor Interest:** High investor search volume indicates strong interest in UNH, which can lead to price volatility.
*   **Q3 Performance:** Articles analyzing UNH's Q3 performance offer insights into recent financial results and future expectations.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.93)
*   **Target Price:** Average: 366.56, High: 626.00, Low: 198.00
*   **Recent Rating Changes:** No changes were specified.

**Analysis:** Analyst consensus remains positive with a "Buy" rating. However, the wide range in target prices indicates uncertainty among analysts regarding the stock's future performance.

### 5. Recent Earnings Analysis

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-08-11 | 3.76 | $111.62B    |
| 2025-05-07 | 6.90 | $109.58B    |
| 2024-11-04 | 6.56 | $100.82B    |
| 2024-08-09 | 4.58 | $98.86B    |
| 2025-08-11 | 4.58 | $98.86B    |

**Analysis:** Revenue has shown consistent growth over the past few quarters. Earnings Per Share (EPS) has fluctuated, but the overall trend appears positive. The latest EPS of 3.76 with revenue of $111.62B indicates potentially reduced profitability in the most recent quarter compared to previous quarters with higher EPS.

### 6. Financial Information: Revenue and Profitability & Capital and Profitability

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
|------------|------------|---------------|
| 2025-06-30 | $111.62B   | 17.93%        |
| 2025-03-31 | $109.58B   | 21.70%        |
| 2024-12-31 | $100.81B   | 21.14%        |
| 2024-09-30 | $100.82B   | 22.84%        |
| 2024-06-30 | $98.86B    | 22.31%        |

**Capital and Profitability:**

| Quarter    | Equity     | ROE   |
|------------|------------|-------|
| 2025-06-30 | $94.72B   | 3.60% |
| 2025-03-31 | $95.04B   | 6.62% |
| 2024-12-31 | $92.66B   | 5.98% |
| 2024-09-30 | $94.53B   | 6.41% |
| 2024-06-30 | $89.36B   | 4.72% |

**Analysis:**

*   **Revenue and Profitability:** Revenue has been steadily increasing, but the profit margin has seen a recent decrease. The latest profit margin of 17.93% is lower than previous quarters, suggesting potential cost pressures or changes in business mix.
*   **Capital and Profitability:** Equity has generally increased over the period, reflecting growth in the company's net assets. However, the Return on Equity (ROE) has fluctuated, with a recent decrease in the latest quarter. This may indicate less efficient use of equity to generate profits in the most recent period.

### 7. Overall Assessment

**Summary:**

UnitedHealth Group (UNH) is currently exhibiting mixed signals. While analysts maintain a "Buy" rating and revenue continues to grow, the stock has significantly underperformed the S&P 500. Recent financial data indicates declining profit margins and ROE, which are concerning. Technical indicators are neutral to slightly bearish, and the expected return is significantly negative.

**Key Concerns:**

*   **Underperformance:** The significant underperformance relative to the S&P 500 is a major concern.
*   **Declining Profitability:** Decreasing profit margins and ROE indicate potential issues with cost management or efficiency.
*   **Negative Expected Return:** The highly negative expected return suggests a long-term outlook of underperformance.

**Potential Positives:**

*   **Revenue Growth:** Continued revenue growth demonstrates the company's ability to generate sales.
*   **Analyst Ratings:** Positive analyst ratings provide some confidence in the company's future potential.
*   **Strong Market Position:** UnitedHealth Group remains a dominant player in the healthcare industry.
*   **Optum Growth:** Expansion in Optum segment can serve as a future growth driver

**Recommendation:**

Based on this analysis, a cautious approach is warranted. While analyst ratings are positive, the recent underperformance and declining profitability indicators suggest potential challenges. I would recommend further research and monitoring of financial performance before making any investment decisions. Also, carefully consider the negative expected return in the context of your investment horizon and risk tolerance.
